| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants
Patent for composition of matter and use of Infectimune® based influenza vaccines granted in the United States
PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or "the Company"), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell-activating platforms, today announced the publication of preclinical research and a patent granted by the United States Patent and Trademark Office (USPTO) that strengthen the foundation of the Company's infectious disease vaccine platform Infectimune®.
Preclinical research published in Vaccines demonstrated that the recombinant protein influenza vaccine Flublok® combined with Infectimune® (R-DOTAP) significantly promoted improved quantity and quality of potent multifunctional CD4 T cells when compared to infectious disease adjuvants. The research concluded that Infectimune® is a leading candidate for use in the next generation of preventive vaccines that may provide more effective and broader protection than current vaccines allow. Infectimune® is being used in PDS0202, the Company's universal influenza vaccine intended to provide broad protection against multiple flu strains.
"Recently published preclinical research shows that Infectimune® overcomes the limitations of current vaccines by promoting CD4+ T cells, known to target many viral proteins and highly conserved regions of viruses," said Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech. "Prior preclinical studies of Infectimune® based influenza vaccines have also shown its potential to provide several advantages over existing influenza vaccines through the induction of broad cross-protective immunity to different subtypes of influenza. We believe this represents a significant advancement in the potential to protect against influenza, its mutations or antigenic drifts."
Additionally, the USPTO granted U.S. Patent Number 11,904,015 titled, "Vaccine Compositions and Methods of Use," directed to vaccine compositions employing the Infectimune® platform and influenza antigens to elicit T cells and antibodies in February 2024. The patent protects compositions containing the Infectimune® platform and influenza antigens and methods of using the Infectimune® platform with pathogenic antigens generally.
"This patent adds to the intellectual property governing our novel investigational universal influenza vaccine," continued Dr. Bedu-Addo. "Possessing multiple layers of intellectual property for our assets is an important value driver for PDS Biotech and is a key component of our business strategy."
About Infectimune®
Infectimune® is a novel investigational immune activating platform that generates broad and robust antibody and T-cell responses that provide durable protection against infectious disease. Infectimune® based vaccines are given by intramuscular injection and generate robust and durable protection against infectious agents in preclinical studies. Infectimune® based vaccines have demonstrated safety in preclinical studies and appear to provide more robust and longer-lasting protection against infectious disease.
Posted In: PDSB
